We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Physiological Phenotyping of Respiratory Outcomes in Infants Born Premature (P3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03906708
Recruitment Status : Recruiting
First Posted : April 8, 2019
Last Update Posted : January 21, 2022
Sponsor:
Collaborators:
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Robert Tepper, Indiana University

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to examine if infants are more likely to suffer from respiratory complications during their first year of life due to being born premature.

Condition or disease Intervention/treatment
Premature Lungs Other: Diffusion Capacity of the Lung for Carbon Monoxide (DLCO)

Detailed Description:
The overall objective of this study is to determine if infant respiratory morbidities after preterm birth are highly variable due to differential impairment of airway, parenchymal and vascular development that can be characterized as distinct physiologic phenotypes. If the nature and severity of these specific impairments of lung function are strongly associated with increased respiratory morbidities during infancy and that proteomic biomarkers can enhance the physiologic characterization of phenotype and prediction of late respiratory outcomes.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 225 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Physiological Phenotyping of Respiratory Outcomes in Infants Born Premature
Actual Study Start Date : January 1, 2019
Estimated Primary Completion Date : January 2023
Estimated Study Completion Date : January 2024
Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Premature Infants
Premature infants born between 24+0 and 36+6 weeks of gestation.
 Other: Diffusion Capacity of the Lung for Carbon Monoxide (DLCO)
Infant lung function testing


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Infant lung development measured by diffusion lung capacity (DLCO). [ Time Frame: By 5 months CGA. ]
    To characterize respiratory phenotypes through specific physiologic measures that quantify and identify predominant small airways, parenchymal and vascular dysfunction at 4 months CA and determine whether these phenotypes define risks for late respiratory morbidity during infancy.


Biospecimen Retention:   Samples With DNA
Proteomics analysis

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   24 Weeks to 36 Weeks   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Recruiting infants born between 24+0 and 36+6 weeks gestational age
Criteria

Inclusion Criteria:

  • Infants born to mothers who are between the gestational ages of 24+0 and 36+6 weeks.

Exclusion Criteria:

  • Cardiopulmonary defects
  • Chromosomal defects
  • Structural abnormalities of the upper airway, chest wall, or lungs
  • Neurological/Neuromuscular disorders
  • Infant not considered viable
  • Family unlikely to be available for long term follow up
  • Mothers under the age of 18.
  • Non English speaking
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03906708


Contacts
Layout table for location contacts
Contact: Jeff Bjerregaard, RRT-NPS 317 944 0192 jbjerreg@iu.edu
Contact: Lisa Bendy, BA, RPFT 317 278 7152 lbendy@iu.edu

Locations
Layout table for location information
United States, Indiana
Jeff Bjerregaard Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Jeff Bjerregaard, RRT-NPS    317-944-0192    jbjerreg@iu.edu   
Contact: Christina Tiller, RRT-CCRC    317 944 4522    ctiller@iu.edu   
Sponsors and Collaborators
Indiana University
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
Layout table for investigator information
Principal Investigator: Robert Tepper, MD Indiana University School of Medicine
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Robert Tepper, Professor of Pediatrics, MD, PhD, Indiana University
ClinicalTrials.gov Identifier: NCT03906708    
Other Study ID Numbers: 1809404763
1R01HL145679-01A1 ( U.S. NIH Grant/Contract )
First Posted: April 8, 2019    Key Record Dates
Last Update Posted: January 21, 2022
Last Verified: January 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Premature Birth
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications
Carbon Monoxide
 Antimetabolites
Molecular Mechanisms of Pharmacological Action
Gasotransmitters
Neurotransmitter Agents
Physiological Effects of Drugs